Journey Medical Corporation Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
Jun. 30, 2026
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 13. COMMITMENTS AND CONTINGENCIES License Agreements The Company has undertaken to make contingent milestone payments to the licensors of its portfolio of drug products and candidates. In addition, the Company is required to pay royalties to such licensors based on a percentage of net sales of each drug candidate following regulatory marketing approval. For additional information on future milestone payments and royalties, see Note 6. Vendor Dispute The Company is involved in an ordinary course proceeding arising from a dispute with a former vendor over certain service-related charges. Due to the inherent uncertainties of matter, the Company is unable to predict the outcome of the matter at this time. Furthermore, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from this matter. However, in the event of unexpected further developments, it is possible that the ultimate resolution of this matter, if unfavorable, may have a material impact on our business, financial condition, results of operations or liquidity.

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2026

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

NOTE 13. COMMITMENTS AND CONTINGENCIES

License Agreements

The Company has undertaken to make contingent milestone payments to the licensors of its portfolio of drug products and candidates. In addition, the Company is required to pay royalties to such licensors based on a percentage of net sales of each drug candidate following regulatory marketing approval. For additional information on future milestone payments and royalties, see Note 6.

Vendor Dispute

The Company is involved in an ordinary course proceeding arising from a dispute with a former vendor over certain service-related charges. Due to the inherent uncertainties of matter, the Company is unable to predict the outcome of the matter at this time. Furthermore, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from this matter. However, in the event of unexpected further developments, it is possible that the ultimate resolution of this matter, if unfavorable, may have a material impact on our business, financial condition, results of operations or liquidity.